Nano-X Imaging Ltd is a medical technology company that provides an integrated end-to-end platform for 3D medical imaging, AI diagnostics, cloud infrastructure, and teleradiology services. The company’s core product is the Nanox.ARC, a 3D multi-source digital tomosynthesis imaging system designed for routine CT scans. Its software suite, Nanox AI, utilizes FDA-cleared and CE-marked algorithms to analyze imaging data for early signs of chronic diseases. The company operates Nanox.CLOUD for secure data management and analytics, and Nanox.MARKETPLACE, a decentralized marketplace connecting imaging facilities with remote radiologists and cardiologists. Through its subsidiary Nanox Health IT, formerly Vaso Healthcare IT Corp, the company provides healthcare IT infrastructure, cybersecurity, and workflow optimization services to hospitals and imaging centers in the United States. Nano-X Imaging serves healthcare providers, radiology groups, and hospitals globally, with a specific focus on expanding access to preventive care in the U.S. market. The company was incorporated in 2018 and acquired key assets from its predecessor, Nanox Imaging PLC, in 2019. It completed the acquisition of USARAD Holdings, Inc. in 2021 to expand its teleradiology network and acquired Zebra Medical Vision Ltd., now Nanox AI, in the same year to bolster its AI capabilities.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Medical Devices Homepage nanox.vision
Sector Healthcare IR page investors.nanox.vision
Tags
medical imaging, artificial intelligence, teleradiology, cloud computing, healthcare it, diagnostics, preventive care, digital tomosynthesis, cybersecurity, workflow optimization, Nanox.ARC, Nanox AI, Nanox.CLOUD, Nanox.MARKETPLACE, Nanox Health IT, USARAD Holdings Inc., Zebra Medical Vision Ltd., Vaso Healthcare IT Corp., Nanox Impact Inc., MDWEB
Press page —

Metrics

Valuation  
Market cap $ 31.528M
Market cap (USD) $ 31.528M
P/E -0.39
PEG —
P/BV 0.44
P/S 2.42
P/OCF -0.77
P/FCF -0.70
Dividend yield —
Turnover / mcap —
Returns  
ROE -45.6%
ROI -52.5%
ROIC -41.1%
Profit margin -576.1%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 44
Quality score -40.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 13.021M 11.283M 9.905M 8.578M 1.304M — —
Net profit -75.018M -53.516M -60.776M -113.243M -61.798M -43.815M -22.563M
Free cash flow -45M -39.365M -48.08M -50.556M -61.229M -35.424M -5.649M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 2.8 7.2 6.37 7.38 14.54 45.66 —
Price performance 12m -0.61 0.13 -0.14 -0.49 -0.68 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Borrowings, current (USD) — — — — 145,000 — 3.49M 3.06M 3.14M
Borrowings, non-current (USD) — — — — — 3.48M — — —
Lease liabilities (USD) — — 526,000 1.44M 50.1M 9.48M 4.91M 4.39M 4.72M
Cash and deposits (USD) 65,000 5,000 8.07M 213M 66.6M 38.5M 56.4M 39.3M 49.2M
Intangible assets (USD) — — — — 102M 91.2M 80.6M 70M 59.9M
Right-of-use assets (USD) — — 526,000 1.36M 1.73M 1.16M 4.57M 3.84M 3.52M
Net debt (borrowings + leases - cash) (USD) — — — — -16.4M -29.8M -48M -31.9M -41.3M
Cash flow detail
Operating cash flow (USD) — -3.67M -5.52M -21.5M -38.1M -43.4M -44.8M -36.6M -40.8M
Purchases of property, plant and equipment (USD) — -73,000 -125,000 -13.9M -23.2M -7.17M -3.3M -2.77M -4.21M
Change in receivables (cash effect) (USD) — — — — -40,000 74,000 -507,000 -321,000 107,000
Change in inventories (cash effect) (USD) — — — — — — — -277,000 -325,000
Change in payables (cash effect) (USD) — — 970,000 2.36M -719,000 10.4M — — —
Income taxes paid (cash effect) (USD) — — — -8,000 -7,000 -147,000 -3,000 -53,000 -184,000
Share-based compensation (USD) — 115,000 16.2M 24.8M 18.8M 18.6M 6.84M 7.26M 4.19M
Operating cash flow before change in receivables (USD) — — — — -38M -43.5M -44.3M -36.3M -40.9M
Free cash flow (OCF - PPE - intangibles) (USD) — -3.74M -5.65M -35.4M -61.2M -50.6M -48.1M -39.4M -45M
Income detail
Research and development expense (USD) — 672,000 2.72M 9.21M 17.1M 26.5M 26M 20.2M 19.2M
↳ 5y CAGR +107.8% +49.3% +15.9%
Total comprehensive income (USD) — — -22.6M -43.8M -62.4M -115M -59.1M -53.2M -75M
Comprehensive income to owners (USD) — — -22.6M -43.8M -62.4M -115M -59.1M -53.2M -75M
Reported Apr 6, 2021 Apr 6, 2021 May 2, 2022 May 1, 2023 May 1, 2023 Apr 22, 2024 Apr 22, 2024 Apr 9, 2025 Apr 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Standby Equity Purchase Agreements Bull 2 Bear 5 Financing

On November 12, 2026, NANO-X IMAGING LTD (the “Company”) entered into two Standby Equity Purchase Agreements with YA II PN, Ltd., a Cayman Islands exempt limited company (the “Investor”): a standby equity purchase agreement providing for sales of up to $40,000,000 of Ordinary Shares on a private placement basis (the “Resale SEPA”) and a standby equity purchase agreement providing for sales of up to $10,000,000 of Ordinary Shares on a registered primary offering basis (the “Primary SEPA” and, together with the Resale SEPA, the “SEPAs”). Pursuant to the SEPAs, the Company will be able to sell up to an aggregate of $50,000,000 of its ordinary shares, par value NIS 0.01 per share (the “Ordinary Shares”), at the Company’s sole option, from time to time during the applicable commitment periods, subject to the terms and conditions of the respective SEPAs.

The Company may request a purchase of Ordinary Shares under either SEPA by delivering an advance notice to the Investor specifying the number of shares to be sold (an “Advance”). The Company is not obligated to utilize any of the $50,000,000 available under the SEPAs and there are no mandatory minimum Advances or non-usage fees.

The Board approved plan targets a 25%–30% reduction in annualized operating expenses, compared to annualized 2026 GAAP and non-GAAP operating expenses, once fully implemented, expected by the end of Q1 2027

Cost reduction aims to advance four strategic priorities: Nanox.ARC and Nanox Imaging Network (NIN) commercialization; commercial partnerships and business development; operational efficiency; and strengthening financial resources

Cost initiatives are intended to improve resources allocation while preserving critical product-development, regulatory and commercial capabilities

PETACH TIKVA, Israel, November 9, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) ("Nanox" or the "Company"), an innovative medical imaging technology company, today announced that the Board of Directors of the Company (the “Board”) has approved a plan to reduce costs and improve operational efficiency.

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Nano-X Imaging Ltd. (Name of Issuer) Ordinary Shares (Title of Class of Securities) (CUSIP Number) Moshe Moalem 8 Herzl Rosenblum Street, Tel Aviv, L3, 6937952 0545884882 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) 10/29/2026 (Date of Event Which Requires Filing of This Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). SCHEDULE 13D CUSIP No. 1 Name of reporting person Moalem Moshe 2 Check the appropriate box if a member of a Group (See Instructions) (a) (b) 3SEC use only

4Source of funds (See Instructions) PF, OO 5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) 6 Citizenship or place of organization ISRAEL Number of Shares Beneficially Owned by Each Reporting Person With: 7 Sole Voting Power 6,675,413.00 8 Shared Voting Power 0.00 9 Sole Dispositive Power 6,675,413.00 10 Shared Dispositive Power 0.00 11 Aggregate amount beneficially owned by each reporting person 6,675,413.00 12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) 13 Percent of class represented by amount in Row (11) 8.49 % 14 Type of Reporting Person (See Instructions) IN Comment for Type of Reporting Person: The percentage of the class in Item 11, is based upon 78,609,485 Ordinary Shares outstanding as of August 17, 2026, as reported in the Issuer's Proxy Statement for its Annual General Meeting attached as Exhibit 99.1 to its Current Report on Form 6K filed with the Securities and Exchange Commission on August 18, 2026 SCHEDULE 13D Item 1.Security and Issuer (a) Title of Class of Securities: Ordinary Shares (b) Name of Issuer: Nano-X Imaging Ltd. (c) Address of Issuer's Principal Executive Offices: Ofer Tech Park, 94 Shlomo Shmeltzer Road, Petach Tikva, ISRAEL , 4970602. Item 2.Identity and Background (a)Moshe Moalem (b)8, Herzl Rosenblum Street, Tel Aviv, Israel 6937952. (c)Entrepreneur and Investor 8, Herzl Rosenblum Street, Tel Aviv, Israel 6937952. (d) The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) The Reporting Person has not, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

(f)The Reporting Person is an Israeli citizen. Item 3.Source and Amount of Funds or Other Consideration

The Ordinary Shares beneficially owned by the Reporting Person were acquired prior to and following the Issuer's initial public offering, using personal funds or through other transactions. No additional Ordinary Shares were acquired in connection with the filing of this Schedule 13D. The percentage of the class in Item 11, is based upon 78,609,485 Ordinary Shares outstanding as of August 17, 2026, as reported in the Issuer's Proxy Statement for its Annual General Meeting attached as Exhibit 99.1 to its Current Report on Form 6K filed with the Securities and Exchange Commission on August 18, 2026. Item 4.Purpose of Transaction

The Reporting Person acquired the Ordinary Shares beneficially owned by him for investment purposes and intends to review his investment in the Issuer on a continuing basis. The Reporting Person is dissatisfied with the Issuer's performance and the resulting impact on shareholder value. The Reporting Person intends to engage in discussions with the Issuer's management and Board of Directors (the "Board"), as well as other shareholders and interested parties, concerning the Issuer's business, operations, financial performance, strategy, management, corporate governance, Board composition and other matters relating to the Issuer. In particular, the Reporting Person opposes the proposed increase in the Issuer's authorized share capital from 150,000,000 to 450,000,000 Ordinary Shares described in the Issuer's proxy statement furnished to the Securities and Exchange Commission on October 28, 2026, for the special general meeting of shareholders scheduled for November 18, 2026. The Reporting Person is concerned about the scale of the proposed increase, its potential to facilitate substantial further dilution of existing shareholders, and the Issuer's financing strategy and capital allocation in light of its performance and the decline in the trading price of its Ordinary Shares. The Reporting Person currently intends to vote against that proposal and may communicate with the Issuer and other shareholders regarding his opposition. The Reporting Person also intends to request that the Issuer refrain from issuing additional voting shares before the November 2, 2026 record date for that meeting. The Reporting Person is concerned that an issuance immediately before the record date could materially alter the voting composition of the meeting and dilute existing shareholders' voting influence, particularly if accompanied by arrangements or economic incentives connected with approval of the proposals. The Reporting Person may seek information regarding any such issuance and any related arrangements and may consider appropriate legal action to protect shareholder rights. In connection with its communications with the Issuer, the Reporting Person may make recommendations or proposals concerning the Issuer's business, operations, strategy, management and corporate governance, including potential changes to the composition, size or leadership of the Board and/or the Issuer's management. The Reporting Person may also consider, propose, support or oppose the appointment, election or removal of directors, identify or recommend potential director candidates, nominate candidates for election to the Board, submit shareholder proposals, solicit proxies or otherwise seek shareholder support for any such actions, including through a contested election of directors, in each case subject to applicable law and the Issuer's organizational documents. The Reporting Person may communicate with other shareholders and interested parties regarding any of the foregoing matters and may consider coordinating or acting together with other shareholders in connection with potential actions concerning the Issuer, subject to applicable law. Depending on various factors, including the outcome of the discussions described above, the Issuer's financial condition, business, operations and prospects, actions taken by the Issuer's management and Board, market conditions and other factors that the Reporting Person may deem relevant, the Reporting Person may from time to time acquire additional securities of the Issuer, dispose of some or all of the securities beneficially owned by him, or consider, formulate or pursue plans or proposals relating to any of the matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D. As of the date hereof, has not identified any particular candidates for nomination to the Board. Except as described herein, the Reporting Person has no present definitive plans or proposals relating to any of the matters described in paragraphs (a) through (j) of Item 4 of Schedule 13D. The Reporting Person reserves the right to review or reconsider his position and to formulate, modify or pursue plans or proposals with respect to any of the foregoing matters at any time, subject to applicable law. Item 5.Interest in Securities of the Issuer (a) (a) Aggregate Number and Percentage of the Class of Securities Identified6,675,413 ordinary shares. The Reporting Person directly holds 5,678,682 Ordinary Shares. An additional 996,731 Ordinary Shares are held by Tanir Corporation BVI, a company wholly owned and controlled by the Reporting Person. The Reporting Person possesses sole voting and dispositive power over the Ordinary Shares held by Tanir Corporation BVI and may therefore be deemed to beneficially own such shares. (b) (i) sole power to vote or to direct the vote: See Item 7 on the cover page(s) hereto. (ii) shared power to vote or to direct the vote: See Item 8 on the cover page(s) hereto. (iii) sole power to dispose or to direct the disposition of: See Item 9 on the cover page(s) hereto. (iv) shared power to dispose or to direct the disposition of: See Item 10 on the cover page(s) hereto. (c)No transaction in the Ordinary Shares of the Issuer were effected during the past sixty days by the Reporting Person. (d) No other person is known to the Reporting Person to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Ordinary Shares of the Issuer covered by this Schedule 13D. (e)Not applicable. Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer There are no contracts, arrangements, understandings or relationships between the Reporting Person and the Issuer. Item 7.Material to be Filed as Exhibits. Not Applicable.

SIGNATURE 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Moalem Moshe

Signature:/s/ Moshe Moalem Name/Title:Moshe Moalem Date:10/29/2026

Prompts

Nano-X Imaging Ltd (ticker NNOX), listed in United States.